Systematic review: Identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring - Predictors and predictive models of disease progression

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 8, 2014, Pages 863-879

  Konerman, M A ^a   Yapali, S ^a   Lok, A S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; ANTIVIRUS AGENT;

AGE; ANALYTICAL PARAMETERS; ASPARTATE AMINOTRANSFERASE ALANINE AMINOTRANSFERASE RATIO; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ACTIVITY; DISEASE COURSE; EARLY INTERVENTION; EVALUATION STUDY; FOLLOW UP; HEPATITIS C; HISTOLOGY; HUMAN; INCIDENCE; LIVER FIBROSIS; MORTALITY; OUTCOMES RESEARCH; PATIENT IDENTIFICATION; PREDICTION; PREDICTOR VARIABLE; REVIEW; STEATOSIS; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; BIOLOGICAL MODEL; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; PATHOLOGY; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 84907905914     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12921     Document Type: Review

References (41)

1. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
2. Janssen Therapeutics. Olysio (simeprevir): Full prescribing information, 2013.
3. Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C; 2010 January 11, 2010.
4. Moyer VA,. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 349-57.
5. Smith BD, Morgan RL, Beckett GA, et al,. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 4: 1-32.
6. Gilead. U.S. Food and Drug Administration Approves Gildead's Sovaldi (Sofosbuvir) for the Treatment of Chronic Hepatitis C, 2013.
7. Janssen Therapeutics. Olysio: There are affordable options available, 2013.
8. Murphy EL,. The increasing burden of mortality from viral hepatitis in the United States. Ann Intern Med 2012; 157: 149-50; author reply 150.
9. Moher D, Liberati A, Tetzlaff J, Altman DG,. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8: 336-41.
10. Bruix J, Sherman M,. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
11. Higgins J, Green R,. Cochrane handbook for systematic reviews of interventions version 5.0.2, 2009.
12. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M,. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses, 2009.
13. Baran B, Gulluoglu M, Soyer OM, et al,. Treatment failure may lead to accelerated fibrosis progression in patients with chronic hepatitis C. J Viral Hepatitis 2014; 21: 111-20.
14. Boccato S, Pistis R, Noventa F, Guido M, Benvegnu L, Alberti A,. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepatitis 2006; 13: 297-302.
15. Bruno S, Zuin M, Crosignani A, et al,. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol 2009; 104: 1147-58.
16. Castera L, Hezode C, Roudot-Thoraval F, et al,. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
17. Colletta C, Smirne C, Fabris C, et al,. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005; 42: 838-45.
18. Cross TJ, Quaglia A, Hughes S, Joshi D, Harrison PM,. The impact of hepatic steatosis on the natural history of chronic hepatitis C infection. J Viral Hepatitis 2009; 16: 492-9.
19. Dienstag JL, Ghany MG, Morgan TR, et al,. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54: 396-405.
20. Everhart JE, Lok AS, Kim HY, et al,. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology 2009; 137: 549-57.
21. Fabris C, Falleti E, Cussigh A, et al,. The interleukin 28B rs12979860 C/T polymorphism and serum cholesterol as predictors of fibrosis progression in patients with chronic hepatitis C and persistently normal transaminases. J Med Virol 2012; 84: 747-55.
22. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L,. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41: 82-7.
23. Fontana RJ, Dienstag JL, Bonkovsky HL, et al,. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut 2010; 59: 1401-9.
24. Ghany MG, Kim HY, Stoddard A, Wright EC, Seeff LB, Lok AS,. Predicting clinical outcomes using baseline and follow-up laboratory data from the hepatitis C long-term treatment against cirrhosis trial. Hepatology 2011; 54: 1527-37.
25. Ghany MG, Kleiner DE, Alter H, et al,. Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124: 97-104.
26. Ghany MG, Lok AS, Everhart JE, et al,. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138: 136-46.
27. Giannini E, Risso D, Botta F, et al,. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003; 163: 218-24.
28. Khouri ST, Perez RM, de Oliveira PM, et al,. Rebiopsy in patients with untreated hepatitis C: a useful procedure. J Clin Gastroenterol 2006; 40: 347-52.
29. Kurosaki M, Matsunaga K, Hirayama I, et al,. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008; 48: 736-42.
30. Levine RA, Sanderson SO, Ploutz-Snyder R, et al,. Assessment of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006; 4: 1271-7.
31. Livingston SE, Deubner H, Bruden DL, et al,. Factors associated with the progression of fibrosis on liver biopsy in Alaska Native and American Indian persons with chronic hepatitis C. Can J Gastroenterol 2010; 24: 445-51.
32. Mummadi RR, Petersen JR, Xiao SY, Snyder N,. Role of simple biomarkers in predicting fibrosis progression in HCV infection. World J Gastroenterol 2010; 16: 5710-5.
33. Perumalswami P, Kleiner DE, Lutchman G, et al,. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 2006; 43: 780-7.
34. Rincon D, Lo Iacono O, Tejedor M, et al,. Prognostic value of hepatic venous pressure gradient in patients with compensated chronic hepatitis C-related cirrhosis. Scand J Gastroenterol 2013; 48: 487-95.
35. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC,. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451-5.
36. Sinn DH, Gwak GY, Shin JU, et al,. Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels. World J Gastroenterol 2013; 19: 2256-61.
37. Sinn DH, Paik SW, Kang P, et al,. Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int 2008; 28: 1363-9.
38. Tamaki N, Kurosaki M, Tanaka K, et al,. Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. J Viral Hepatitis 2013; 20: 72-6.
39. Van Der Meer AJP, Hansen BE, Feld JJ, et al,. Prediction of long-term survival in chronic Hepatitis C patients with advanced fibrosis using standard laboratory tests. J Hepatol 2012; 56: S363.
40. Vergniol J, Foucher J, Terrebonne E, et al,. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-9, 1979 e1-3.
41. Williams MJ, Lang-Lenton M,. Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepatitis 2011; 18: 17-22.